Arcus Biosciences, Inc.
RCUS
$28.74
$0.020.07%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -55.34% | 67.38% | -4.26% | -8.75% | 6.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -55.34% | 67.38% | -4.26% | -8.75% | 6.07% |
| Cost of Revenue | 2.47% | 13.45% | 16.74% | 14.32% | 21.55% |
| Gross Profit | -70.40% | 10.31% | -45.26% | -48.59% | -46.71% |
| SG&A Expenses | -7.83% | -4.31% | -8.33% | -7.44% | -4.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.50% | 9.88% | 11.44% | 9.63% | 15.38% |
| Operating Income | -43.79% | 8.72% | -24.52% | -25.84% | -23.81% |
| Income Before Tax | -54.88% | 5.38% | -25.18% | -26.39% | -20.73% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -66.67% |
| Earnings from Continuing Operations | -54.36% | 5.63% | -24.73% | -26.30% | -19.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.36% | 5.63% | -24.73% | -26.30% | -19.68% |
| EBIT | -43.79% | 8.72% | -24.52% | -25.84% | -23.81% |
| EBITDA | -45.12% | 8.69% | -25.33% | -26.74% | -24.24% |
| EPS Basic | 9.37% | -3.11% | -43.22% | -44.87% | -39.02% |
| Normalized Basic EPS | -23.60% | 23.85% | -15.56% | -17.59% | -11.75% |
| EPS Diluted | 9.37% | -3.11% | -43.22% | -44.87% | -39.02% |
| Normalized Diluted EPS | -23.60% | 23.85% | -15.56% | -17.59% | -11.75% |
| Average Basic Shares Outstanding | 22.94% | 22.52% | 19.17% | 17.17% | 18.57% |
| Average Diluted Shares Outstanding | 22.81% | 22.62% | 19.28% | 17.28% | 18.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |